Keyword: NuvaRing

13. NuvaRing

After a 2001 approval and billions in sales, Merck’s NuvaRing is coming to the end of its patent life this year. But it’s not clear whether any generic drugmakers will be able to launch when that patent expires, as two would-be copycats say they expect to introduce theirs in 2019.